Core Insights - Actuate Therapeutics, Inc. announced that data from its Phase 2 study of elraglusib in metastatic pancreatic cancer will be presented at the 2026 ASCO GI Cancers Symposium [1] - The study evaluates elraglusib in combination with gemcitabine/nab-paclitaxel, a standard chemotherapy regimen for this type of cancer [1] Presentation Details - Oral Presentation: Results from the randomized Phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated metastatic pancreatic ductal adenocarcinoma [2] - Date/Time: January 9, 2026, 4:15 PM-5:00 PM (PST) [2] - First Author: Devalingam Mahalingam, MD, PhD, Gastrointestinal Oncologist at Northwestern University [2] Poster Presentation - Title: Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with elraglusib and gemcitabine/nab-paclitaxel [3] - Date/Time: January 9, 2026, 11:30 AM-1:00 PM; 5:00 PM-6:00 PM (PST) [4] - First Author: Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics [4] Company Overview - Actuate Therapeutics is focused on developing therapies for high-impact, difficult-to-treat cancers [4] - The lead investigational drug, elraglusib, is a novel GSK-3β inhibitor targeting pathways involved in tumor growth and resistance to conventional therapies [4]
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026